PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE's minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology. Of note, China recently adopted a n

PolarityTE Receives Notice of Allowance for Chinese Patent

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock?

The stock price of PolarityTE Inc (NASDAQ: PTE) decreased by over 12% pre-market. This is why it happened.

PolarityTE (PTE) Stock: Over 12% Decrease Pre-Market Explanation

PolarityTE Inc (NASDAQ: PTE) reported a Q1 EPS loss of $(0.24), missing the consensus of $(0.12) loss, but better than $(0.39) loss a year ago. Sales of $4.71 million increased 31% sequentially and over 400% on a Y/Y basis.

PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway

PolarityTE, Inc. (PTE) CEO David Seaburg on Q1 2021 Results - Earnings Call Transcript

PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of 7.69% and 88.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE, Inc. (PTE) Reports Q1 Loss, Tops Revenue Estimates

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the first quarter ended March 31, 2021. Business Update Reiterates previous guidance on Investigational New Drug (IND) submission in 2H:21 Plans to wind down commercial sales of SkinTE® consistent with FDA enforcement discretion period ending on May 31, 2021 Expects substantial spend

PolarityTE Reports First Quarter Results and Provides Business Update

PolarityTE (PTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why PolarityTE (PTE) Might Surprise This Earnings Season

Cellect Biotechnology Ltd

CKX Lands

Cue Biopharma

Eltek

SemiLEDs

Obalon Therapeutics

Precipio

Protagenic Therapeutics

Regional Health Properties

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on InvestorPlace.

Market Update: The 10 Most Volatile Stocks Today

PolarityTE (NASDAQ: PTE) shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints. In the company's multi-center randomized controlled trial, 70% of patients treated with SkinTE plus standard of care showed wound closure at 12 weeks, compared with 34% of patients receiving standard of care alone.

Why PolarityTE Shares Are Trading Higher On Monday

ConforMIS

These penny stocks just released big news; will they be on your watchlist? The post Best Penny Stocks to Buy?

Best Penny Stocks to Buy? 3 With Big News Today

PolarityTE Inc (NASDAQ: PTE) has announced preliminary topline data from a multi-center randomized controlled trial evaluating SkinTE for the treatment of Diabetic Foot Ulcers. The 100-subject trial, which assessed SkinTE plus standard of care (SOC) vs.

PolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881254) met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) at 12 weeks. 100 patients were evaluated across 13 sites with 50 patients receiving SkinTE plus SOC and 50 pat

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on May 13, 2021 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing 1-800-377-1217 (U.S. and Canada) or +44 (0)330 027 2386 (International) with confirmation code 231666

PolarityTE to Report First Quarter Financial Results on May 13, 2021

Like all microcap biotechs, PolarityTE is a very risky bet. But they have a product with the potential to revolutionize wound care. This is a giant addressable market.

PolarityTE: Risk And Reward

PolarityTE, Inc. (PTE) CEO David Seaburg on Q4 2020 Results - Earnings Call Transcript

Shares of PolarityTE (NASDAQ:PTE) fell 2.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 64.47% over the past year to ($0.27), which missed the estimate of ($0.16).

Recap: PolarityTE Q4 Earnings

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. David Seaburg, Chief Executive Officer, commented, “2020 was a transformational year for PolarityTE as we made the decision to pursue an IND and BLA for SkinTE. If we successfully obtain a BLA for SkinTE, we believe it will create a more valuable asset wi

PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results

PolarityTE (NASDAQ:PTE) announces its next round of earnings this Tuesday, March 30. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

PolarityTE's Earnings Outlook

PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on March 30, 2021 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 336 9104 (International) with confirmation code 3633

PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021

PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021. A webcast of the presentation will be available on March 9, 2021 beginning at 7:00 a.m. Eastern Time and can be accessed in the "News & Media/Events" section of PolarityTE's website at www.polarityte.com/news-media/events or

PolarityTE to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Revance Therapeutics

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

News for PolarityTE Inc Stock (PTE)